Carregant...
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV lung...
Guardat en:
| Publicat a: | Cancer Manag Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5937504/ https://ncbi.nlm.nih.gov/pubmed/29760563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S148009 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|